Imugene (ASX:IMU) Other Gross PPE : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Imugene Other Gross PPE?

Imugene's Other Gross PPE for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Imugene's quarterly Other Gross PPE increased from Dec. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.90 Mil) but then declined from Jun. 2023 (A$0.90 Mil) to Dec. 2023 (A$0.00 Mil).

Imugene's annual Other Gross PPE declined from Jun. 2022 (A$1.18 Mil) to Jun. 2023 (A$0.90 Mil) but then increased from Jun. 2023 (A$0.90 Mil) to Jun. 2024 (A$2.07 Mil).

Imugene Other Gross PPE Historical Data

The historical data trend for Imugene's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene Other Gross PPE Chart

Imugene Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Other Gross PPE

Get a 7-Day Free Trial

0.21

0.65

1.18

0.90

2.07

Imugene Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Gross PPE	Get a 7-Day Free Trial															1.18	-	0.90	-	2.07

Imugene Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Imugene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

IUGNF:USA ILA:Germany

Address

4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000

Website

https://www.imugene.com

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

Imugene Headlines

No Headlines